You have accessJournal of UrologyCME1 Apr 2023MP13-07 AQUABLATION THERAPY® VS TRANSURETHRAL RESECTION OF THE PROSTATE: 5-YEAR OUTCOMES OF THE WATER RANDOMIZED CLINICAL TRIAL FOR MEDIUM-SIZED PROSTATES Kussil Oumedjbeur, Ahmed Ibrahim, Imad Matta, David-Dan Nguyen, Adel Arezki, Iman Sadri, David Bouhadana, Tawfik Elsherbini, Peter Gilling, Neil Barber, Mihir Desai, Alexis E. Te, Claus G. Roehrborn, and Kevin C. Zorn Kussil OumedjbeurKussil Oumedjbeur More articles by this author , Ahmed IbrahimAhmed Ibrahim More articles by this author , Imad MattaImad Matta More articles by this author , David-Dan NguyenDavid-Dan Nguyen More articles by this author , Adel ArezkiAdel Arezki More articles by this author , Iman SadriIman Sadri More articles by this author , David BouhadanaDavid Bouhadana More articles by this author , Tawfik ElsherbiniTawfik Elsherbini More articles by this author , Peter GillingPeter Gilling More articles by this author , Neil BarberNeil Barber More articles by this author , Mihir DesaiMihir Desai More articles by this author , Alexis E. TeAlexis E. Te More articles by this author , Claus G. RoehrbornClaus G. Roehrborn More articles by this author , and Kevin C. ZornKevin C. Zorn More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003233.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The WATER trial previously introduced Aquablation® as a safe and effective TURP alternative in the management of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) for prostates <80 mL. To date, no long-term superiority endpoints have been reported for medium-sized prostates. In this subset analysis of the WATER cohort, we aim to compare the 5-year efficacy and safety of Aquablation® vs. TURP for the management of 50-80 mL prostates. METHODS: WATER is a double-blinded, multicenter and prospective randomized-controlled clinical trial for prostates 30-80 mL. 96 men with prostates 50-80 mL randomized to either Aquablation Therapy® or TURP from the initial cohort were retained for the subset analysis. Men received follow-up at 1, 3, 6 and 12 months, then annually up to 5 years. The primary efficacy endpoint was reduction of IPSS at 5-year follow-up. The primary safety endpoint was the occurrence of Clavien-Dindo postoperative complications grade 1 persistent (CD1P) and grade 2 (CD2) or higher at 6 months. Other measures included QoL, Qmax, PVR and MSHQ-EjD. RESULTS: Both study groups had comparable baseline voiding parameters and clinical demographics. Overall reduction in IPSS score was significantly higher in the Aquablation group across 5 years of follow-up (-14.1 vs. -10.8, p=0.02). Changes in QoL, Qmax and PVR were similar across groups (p>0.05). The Aquablation group displayed no changes in MSHQ-EjD score, while TURP yielded poorer questionnaire scores across all follow-ups (0.6 vs -2.1, p=0.01). The Aquablation group achieved a significantly lower rate of CD1P and CD2 or higher events at 6 months (RD=-23.1%; 95% CI [-29.9, -15.5], p=0.018). Among complications, post-operative ejaculatory dysfunction was notably lower in Aquablation® (RD=-21.9%; 95% CI [-32.5, -10.7], p=0.0005), while risk of bleeding was similar. The surgical and medical retreatment rate was also lower in Aquablation® (RD=-14.4%, 95% CI [-2.29, -30.4], p=0.015). CONCLUSIONS: Aquablation Therapy® yields better long-term efficacy and safety outcomes than TURP in the management of LUTS for prostate volumes of 50-80 mL within the WATER trial. This further supports adoption of Aquablation Therapy® over TURP for men with medium-sized prostates. Source of Funding: The trial is funded by PROCEPT BioRobotics. No funding was provided for the abstract creation © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e175 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kussil Oumedjbeur More articles by this author Ahmed Ibrahim More articles by this author Imad Matta More articles by this author David-Dan Nguyen More articles by this author Adel Arezki More articles by this author Iman Sadri More articles by this author David Bouhadana More articles by this author Tawfik Elsherbini More articles by this author Peter Gilling More articles by this author Neil Barber More articles by this author Mihir Desai More articles by this author Alexis E. Te More articles by this author Claus G. Roehrborn More articles by this author Kevin C. Zorn More articles by this author Expand All Advertisement PDF downloadLoading ...